CAR T Cell Functional Enhancement

• 4266 · PDF CAR-T-cell monitoring using specific multimers: a fast and specific method allowing uniform evaluation Elizabeth Epps, Kivin Jacobsen, kevin Lenogue, Liselotte Brix
• 4267 · PDF In vivo evaluation of autologous anti-BCMA CAR-T therapy in PBMC-humanized SDKO mice reveals donor-specific immune responses Alba Matas-Céspedes, Jiwon Yang, Kushal Prajapati, Destanie Rose, Oanh Pham, Michael Lehmann, Tom McKevitt, Georgina Cornish, Richard Stebbings, James G. Keck, Ilian Radichev
• 4268 · PDF Armored allogeneic Epstein-Barr virus specific T cells expressing a multi-functional B7-H3 chimeric antigen receptor exhibit improved persistence, expansion and performance in solid tumor models Marvin Chew, Pei Yun Teo, Joanna Koh, Jin Wei Tan, Lindsay Kua, Richard Ong, Fiona Wong, Angeline Goh, Qingfeng Chen, Cliona Rooney, Ivan Horak, Kar Wai Tan, Lionel Low
• 4269 · PDF Structure-guided protein engineering and humanization of GPC1-targeted nanobody CAR T cells for treating pancreatic cancer Hsi En Tsao, Mitchell Ho
• 4270 · PDF Enhanced solid tumor rejection using IF-BETTER gated CAR T cells for the treatment of hepatocellular carcinoma Leena Halim, Michael Lopez, Michel Sadelain
• 4272 4272 Glutamic-oxaloacetic transaminase 2 (GOT2) as a dual-functional enhancer for CAR-T cell metabolic fitness Xiangyi Fang, Shadab Kazmi, Andre Kelly, Xiaoling Jin, Alison Jaccard, Nathaniel W. Snyder, Alexander A. Shestov, Saba Ghassemi, Roddy S. O'Connor
• 4273 4273 Environmental conditioning during CD19-CAR T cell manufacturing impacts antitumor potency in a subcutaneous NALM6 tumor model Candy Garcia, Anita J. Zaitouna, Abriel Czachorowski, Lauren Kucharczyk, Natalie Czeryba, Philip Edward Lapinski, Andrea Hodgins-Davis, Thomas Sullivan, Yelena Bronevetsky, NINGCHUN LIU, Sheri Barnes, Shannon Eaker, Scott Wise, James Lim
• 4274 · PDF CAR-T cells with GPC3-inducible gene circuits for targeting hepatocellular carcinoma Kin Ching Tsang, Yuqing Deng, Pinghui Zhu, Chenzi Zhang, Jianwei Ren, Bo Feng
• 4275 · PDF Combining circular RNA and a silicon membrane-based cell engineering approach to create CAR-Ts with membrane bound IL-2 and IL-12 Armon Sharei, Zhihui Song, Sophia Hirsch, Eleni Rogers, Darby Kreienberg, Alec Barclay, Andrew Larocque, Anil Narasimha
• 4276 · PDF Synecta™ T1 cell-derived nanoparticles and Flowfect® continuous flow transfection enhance non-viral engineering efficiency and manufacturing scalability of CD19-directed CAR-T cells for hematologic malignancies Chiquita Hanindya, Christopher Abraham, Maria Lai, Peter Keller, Kevin Gutshall
• 4277 · PDF AQP3 NOT gating mitigates lethal on-target off-tumor pulmonary toxicity of MSLN-directed CAR-T cells in ovarian cancer Minghua Xiang, Wei Mu, Bingbing Zhao, Jundong Li, Qinglei Gao, Huayi Li
• 4278 · PDF Regulatory T cell inspired engineering of CAR-T cells enhances anti-tumor efficacy in solid tumors Avik Chattopadhyay, Erin O’Connor, Leonardo M. R. Ferreira
• 4279 4279 A PSMA-targeted CAR-T cell engineered with a CD16A signaling domain mitigates cytokine output while retaining antitumor activity in prostate cancer models Parv Barot, Hittu Matta, Sunju Choi, Gong Songjie, Bryant Bravo, Elton Zho, Hsing-Yu Wu, Sam Lin, Zhuoyue Yang, Preet M. Chaudhary
• 4280 · PDF Restoration of LAT signaling via the ALA-CART platform promotes metabolic resiliency and persistence of AML CAR T cells Catherine Danis, Amanda J. Novak, Etienne Danis, Angie Vazquez, Michael Yarnell, Lillie Leach, M. Eric Kohler
• 4281 · PDF Armoring ROR1 CAR T cells with IL18 improves CAR T cell function and cytotoxicity against pancreatic cancer cell-lines in vitro and in vivo Bal Krishna Chand Thakuri, Saule Nurmukhambetova, Tri Tran, Ngoc Tran, Peirong Hu, Pradyot Dash, Rimas J Orentas, Alun Carter
• 4283 · PDF CD3-positive allogeneic CAR T-cells: A novel platform with persistence, BiTE-capture, and no alloreactivity Tanya Hundal, Yan Luo, Yaqing Qie, Martha E. Gadd, Shaohua Guo, Mohamed A. Kharfan-Dabaja, Hong Qin
• 4284 · PDF FT839: A next-generation, off-the-shelf CAR T cell uniquely engineered with a dual CAR system targeting CD19 and CD38 for the treatment of hematological malignancies and autoimmune diseases without conditioning chemotherapy Alex J. Garcia, Shilpi Chandra, Soheila Shirinbak, Mark Jelcic, Brian Groff, Spas Markov, Alma Gutierrez, Angela Gentile, Miguel Meza, Karina Palomares, Carissa Dege, Bjoern Gaertner, Ramzey Abujarour, John Goulding, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, Jode Goodridge, Martin Hosking
• 4286 · PDF B7-H3 hypoimmune chimeric antigen receptor T cells overcome immune rejection and retain antitumor activity against cholangiocarcinoma Chiara Camillo, Xiaomeng Hu, Giulia Cattaneo, Liti Zhang, Erica Daniels, Luigi Liguori, Eduardo Tejeda-Polanco, Maoyang Qi, Enrica Quattrocchi, Francesco Sabbatino, Sonja Schrepfer, Cristina R. Ferrone
• 4287 · PDF Cell killing dynamics and heterogeneity in engineered T-cells measured in live CellCage enclosures Shawn Levy, Richard Yau, Shreya Deshmukh, JangKeun Kim, Jiwoon Park, Yanping Yang, Makenzie Sacca, Shan Sabri, Christopher E. Mason, Moonsoo M. Jin
• 4288 · PDF Use of a 50-marker mass cytometry intracellular cytokine staining panel reveals unforeseen functional diversity within cell therapy products and unmasks potential efficacy 'saboteurs' Lauren Tracey, Michael Cohen, Laura Polanco, Erika Smith-Mahoney, David King, Amedeo Cappione, Anna Belkina, Christina Loh, Jennifer E. Snyder-Cappione
• 4290 · PDF Harnessing an optimized cellular therapy platform for ALK-expressing pediatric and adult solid tumors Alberto D. Guerra, Geoffrey Rouin, Patrick Ryan, Grant Li, David Groff, Christina Acholla, Matthew Beasley, Lauren A. Pitt, Kayla Hallac, Evan W. Weber, Yael P. Mosse
• 4291 · PDF Synecta™ T1 cell-derived nanoparticles enable accelerated, potent T cell expansion for scalable adoptive immunotherapy manufacturing Deeksha Muthumani, Chiquita Hanindya, Gil Joseph, Victor Carpio, Bakir Valentić, Roddy O' Connor, Olga Barreiro, Ulrich H. Von Andrian, Peter Keller

在会议检索中浏览本分会场